FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083048595> ?p ?o ?g. }

• W2083048595 endingPage "427" @default.
• W2083048595 startingPage "418" @default.
• W2083048595 abstract "Chronic heart failure (CHF) is associated with activation of the sympathetic nervous system. This activation provides short term haemodynamic support to the failing myocardium, but may be deleterious over longer periods as chronic catecholamine excess appears to contribute to disease progression and increased mortality in this condition. Therefore, blockade of sympathetic activation represents a logical, if somewhat counter-intuitive, approach to the management of the patient with systolic CHF. Pharmacological approaches to blockade of this system include inhibition of central sympathetic outflow (using central sympatholytics, e.g. rilmenidine, moxonidine), blockade of the catecholamine biosynthetic pathway (dopamine beta hydroxylase antagonists) and blockade of the cardiac effects of sympathetic activation (beta-adrenoceptor blocking agents). Beta-blockers have now been extensively studied in patients with symptomatic CHF of the New York Heart Association (NYHA) Class II and III severity. Provided beta-blocker therapy is carefully up-titrated from sub-therapeutic doses and given for at least three to four months, these agents have been associated with favourable long term haemodynamic, functional and mortality outcomes. Furthermore, beta-blockers delay disease progression in CHF by reversing the pathological myocardial remodelling process that accompanies the disease. Non-selective beta-adrenoceptor blocking drugs appear to be of particular benefit in CHF therapy. Myocardial beta2 receptors are down-regulated to a lesser extent than beta1 receptors in CHF, therefore blockade of the beta2 receptor sub-type may assume greater importance in inhibiting the deleterious effects of sympathetic activation on the myocardium in this disease. Newer agents that possess additional vasodilator properties (carvedilol, bucindolol, nebivolol) may be useful in overcoming the initial negative inotropy of the beta-blocking component of the drug, however, it is unlikely that vasodilation contributes greatly to long term clinical benefits. Drugs such as carvedilol are also anti-oxidant, anti-proliferative and have anti-endothelin actions; the clinical significance of these properties is yet to be determined. Unanswered questions remain regarding the use of beta-blockers in heart failure. Ongoing studies are further examining mechanisms underlying the clinical benefits of these agents as well as their therapeutic potential in NYHA Class IV patients, heart failure post-myocardial infarction and patients with asymptomatic left ventricular dysfunction." @default.
• W2083048595 created "2016-06-24" @default.
• W2083048595 creator A5021169264 @default.
• W2083048595 date "1999-06-01" @default.
• W2083048595 modified "2023-09-23" @default.
• W2083048595 title "Sympathetic activation and the role of beta-blockers in chronic heart failure" @default.
• W2083048595 cites W1970715302 @default.
• W2083048595 cites W1974311112 @default.
• W2083048595 cites W1981731045 @default.
• W2083048595 cites W1983902487 @default.
• W2083048595 cites W1984193593 @default.
• W2083048595 cites W1988595623 @default.
• W2083048595 cites W2002234003 @default.
• W2083048595 cites W2002730305 @default.
• W2083048595 cites W2004923834 @default.
• W2083048595 cites W2007424418 @default.
• W2083048595 cites W2016532277 @default.
• W2083048595 cites W2023044098 @default.
• W2083048595 cites W2030553750 @default.
• W2083048595 cites W2042235128 @default.
• W2083048595 cites W2044066871 @default.
• W2083048595 cites W2044204833 @default.
• W2083048595 cites W2063106685 @default.
• W2083048595 cites W2065724905 @default.
• W2083048595 cites W2065948729 @default.
• W2083048595 cites W2066441728 @default.
• W2083048595 cites W2071526303 @default.
• W2083048595 cites W2071833353 @default.
• W2083048595 cites W2079983580 @default.
• W2083048595 cites W2083629405 @default.
• W2083048595 cites W2085788358 @default.
• W2083048595 cites W2088138316 @default.
• W2083048595 cites W2117913890 @default.
• W2083048595 cites W2123495845 @default.
• W2083048595 cites W2132359891 @default.
• W2083048595 cites W2319534362 @default.
• W2083048595 cites W2326508838 @default.
• W2083048595 cites W2338638760 @default.
• W2083048595 cites W2516430170 @default.
• W2083048595 cites W4210834519 @default.
• W2083048595 cites W4243147470 @default.
• W2083048595 doi "https://doi.org/10.1111/j.1445-5994.1999.tb00737.x" @default.
• W2083048595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10868514" @default.
• W2083048595 hasPublicationYear "1999" @default.
• W2083048595 type Work @default.
• W2083048595 sameAs 2083048595 @default.
• W2083048595 citedByCount "16" @default.
• W2083048595 countsByYear W20830485952013 @default.
• W2083048595 countsByYear W20830485952017 @default.
• W2083048595 countsByYear W20830485952018 @default.
• W2083048595 countsByYear W20830485952020 @default.
• W2083048595 countsByYear W20830485952021 @default.
• W2083048595 crossrefType "journal-article" @default.
• W2083048595 hasAuthorship W2083048595A5021169264 @default.
• W2083048595 hasConcept C126322002 @default.
• W2083048595 hasConcept C164705383 @default.
• W2083048595 hasConcept C170493617 @default.
• W2083048595 hasConcept C178853913 @default.
• W2083048595 hasConcept C2776533406 @default.
• W2083048595 hasConcept C2777014715 @default.
• W2083048595 hasConcept C2777537511 @default.
• W2083048595 hasConcept C2778198053 @default.
• W2083048595 hasConcept C2778468042 @default.
• W2083048595 hasConcept C2778938600 @default.
• W2083048595 hasConcept C2780074459 @default.
• W2083048595 hasConcept C2780591200 @default.
• W2083048595 hasConcept C71924100 @default.
• W2083048595 hasConcept C84393581 @default.
• W2083048595 hasConceptScore W2083048595C126322002 @default.
• W2083048595 hasConceptScore W2083048595C164705383 @default.
• W2083048595 hasConceptScore W2083048595C170493617 @default.
• W2083048595 hasConceptScore W2083048595C178853913 @default.
• W2083048595 hasConceptScore W2083048595C2776533406 @default.
• W2083048595 hasConceptScore W2083048595C2777014715 @default.
• W2083048595 hasConceptScore W2083048595C2777537511 @default.
• W2083048595 hasConceptScore W2083048595C2778198053 @default.
• W2083048595 hasConceptScore W2083048595C2778468042 @default.
• W2083048595 hasConceptScore W2083048595C2778938600 @default.
• W2083048595 hasConceptScore W2083048595C2780074459 @default.
• W2083048595 hasConceptScore W2083048595C2780591200 @default.
• W2083048595 hasConceptScore W2083048595C71924100 @default.
• W2083048595 hasConceptScore W2083048595C84393581 @default.
• W2083048595 hasIssue "3" @default.
• W2083048595 hasLocation W20830485951 @default.
• W2083048595 hasLocation W20830485952 @default.
• W2083048595 hasOpenAccess W2083048595 @default.
• W2083048595 hasPrimaryLocation W20830485951 @default.
• W2083048595 hasRelatedWork W1994097720 @default.
• W2083048595 hasRelatedWork W2068039044 @default.
• W2083048595 hasRelatedWork W2076125163 @default.
• W2083048595 hasRelatedWork W2083048595 @default.
• W2083048595 hasRelatedWork W2167036398 @default.
• W2083048595 hasRelatedWork W2410081518 @default.
• W2083048595 hasRelatedWork W2892177752 @default.
• W2083048595 hasRelatedWork W3033817661 @default.
• W2083048595 hasRelatedWork W3210782531 @default.
• W2083048595 hasRelatedWork W4234660475 @default.
• W2083048595 hasVolume "29" @default.

• next